Trientine: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
HAS (France) and TLV (Sweden) recommended or restricted trientine, while AOTMIT (Poland) did not recommend it.
Assessment has run over 6.5 years, from 24 Jan 2020 at TLV (Sweden) to 2026 at PBAC (Australia).
PBAC (Australia) changed its position: not recommended in 2021, recommended by 2023, after a resubmission.
No assessment is on file from SMC (Scotland), PHARMAC (New Zealand), AWMSG (Wales) and G-BA (Germany), each among the eight highest-volume agencies here.
Not every gap is a refusal: for trientine, 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 5 of 14 records date from 2023 or later.
6 of these 14 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
TLV (Sweden) was first to assess trientine, on 24 Jan 2020; CIPM (Spain) did not open a file until 16 Dec 2021 — a moderate spread of 1.9 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 7 years in total.
4 of the 5 agencies here assessed trientine more than once, PBAC (Australia) most often at 6 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 5 of the 18 agencies here have assessed trientine.
The full ledger for trientine reads 8 recommended, 4 not recommended, 1 withdrawn and 1 other.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CIPM (Spain) | 29 Jan 2025 | Indicaciones terapéuticas autorizadas: Tratamiento de la enfermedad de Wilson en adultos, adolescentes y niños de 5 años… | financed by the SNS · art. 92 a, c | source |
| PBAC (Australia) | 2024 | Wilson disease | The PBAC extended the May 2022 recommendation for trientine for an additional 12 months. | source |
| HAS (France) | 10 Jan 2024 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
| TLV (Sweden) | 25 Mar 2022 | Trientine Tillomed ingår i högkostnadsskyddet | general subsidy | source |
| AOTMIT (Poland) | 26 Jan 2021 | Cuprior reimbursement recommendation | not recommended | source |
9 further decisions for trientine, across 4 agencies, are not shown here. They include the most recent record on file, 2026 from PBAC (Australia); its outcome is in the subscriber dataset. They link to 4 further source documents.
Related molecules
- teduglutide — same ATC class A16A — Other alimentary tract and metabolism
- sapropterin — same ATC class A16A — Other alimentary tract and metabolism
- miglustat — same ATC class A16A — Other alimentary tract and metabolism
- migalastat — same ATC class A16A — Other alimentary tract and metabolism
- cerliponase alfa — same ATC class A16A — Other alimentary tract and metabolism
- givosiran — same ATC class A16A — Other alimentary tract and metabolism
Coverage: 14 decisions for trientine from 5 agencies, 2020 to 2026. Data to 7 Sep 2026. ATC class A16A — Other alimentary tract and metabolism. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.